Arcturus Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $557.6M

Website: http://www.arcturusrx.com

Clinical Trials

Safety, Tolerability and Efficacy Study of ARCT-032 in People with Cystic Fibrosis

Phase 2

Recruiting

Conditions: Cystic Fibrosis
CFTR Gene Mutation

Interventions: Biological: ARCT-032

First Posted Date: 2024-12-24

Last Posted Date: 2024-12-24

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 12

Registration Number: NCT06747858

Locations: 🇺🇸
The Cystic Fibrosis Institute, Northfield, Illinois, United States

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

Phase 1

Not yet recruiting

Conditions: Influenza, Human

Interventions: Biological: ARCT-2304
Biological: Control vaccine younger adults
Biological: Control vaccine older adults
Other: Placebo Vaccine

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 200

Registration Number: NCT06602531

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Phase 2

Recruiting

Conditions: Ornithine Transcarbamylase Deficiency
OTC Deficiency
OTCD

Interventions: Biological: ARCT-810

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 9

Registration Number: NCT06488313

Locations: 🇺🇸
Uncommon Cures, Chevy Chase, Maryland, United States

Immunogenicity and Safety Study of Self-amplifying MRNA COVID-19 Vaccine Administered with Influenza Vaccines in Adults

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: ARCT-2303
Biological: Influenza vaccine, adjuvanted
Biological: Influenza vaccine
Other: Placebo

First Posted Date: 2024-02-28

Last Posted Date: 2024-12-16

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 1499

Registration Number: NCT06279871

Locations: 🇦🇺
Paratus Clinical Central Coast, Central Coast, New South Wales, Australia
🇦🇺
Australian Clinical Research Network (ACRN), Sydney, New South Wales, Australia
🇦🇺
Emeritus Research Sydney, Sydney, New South Wales, Australia

and more 26 locations

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Phase 1

Active, not recruiting

Conditions: Influenza, Human

Interventions: Biological: ARCT-2138
Biological: Licensed Quadrivalent Vaccine for younger adults
Biological: Licensed Quadrivalent Vaccine for older adults

First Posted Date: 2023-11-09

Last Posted Date: 2024-07-26

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 135

Registration Number: NCT06125691

Locations: 🇦🇺
Emeritus Research Camberwell, Melbourne, Victoria, Australia
🇦🇺
Nucleus Network Brisbane Clinic, Brisbane, Queensland, Australia

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: ARCT-032
Other: Placebo

First Posted Date: 2023-02-03

Last Posted Date: 2024-11-13

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 39

Registration Number: NCT05712538

Locations: 🇳🇿
New Zealand Clinical Research, Christchurch, New Zealand

Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Phase 2

Active, not recruiting

Conditions: OTCD
Ornithine Transcarbamylase Deficiency
OTC Deficiency

Interventions: Biological: ARCT-810
Other: Placebo

First Posted Date: 2022-09-02

Last Posted Date: 2024-07-16

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 24

Registration Number: NCT05526066

Locations: 🇧🇪
Cliniques Universitaires Saint Luc, Bruxelles, Belgium
🇫🇷
Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades, Paris, France
🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy

and more 11 locations

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

Phase 1

Completed

Conditions: SARS-CoV-2 Infection
COVID-19
Corona Virus Infection

Interventions: Biological: ARCT-021
Biological: ARCT-154
Biological: ARCT-165

First Posted Date: 2021-09-08

Last Posted Date: 2024-12-18

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 72

Registration Number: NCT05037097

Locations: 🇸🇬
Arcturus Investigational Site 101, Singapore, Singapore
🇺🇸
Arcturus Investigational Site 202, Wichita, Kansas, United States
🇿🇦
Arcturus Investigational Site 301, Diepkloof, Soweto, South Africa

and more 1 locations

Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

Phase 2

Terminated

Conditions: SARS-CoV-2

Interventions: Biological: ARCT-021

First Posted Date: 2021-01-28

Last Posted Date: 2024-12-30

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 65

Registration Number: NCT04728347

Locations: 🇸🇬
SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital, Singapore, Singapore

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Phase 2

Terminated

Conditions: SARS-CoV Infection
Corona Virus Infection
Covid19

Interventions: Biological: ARCT-021 single dose priming
Biological: ARCT-021 two lower dose priming
Biological: ARCT-021 two higher dose priming
Biological: Placebo (two doses), priming
Biological: Randomized booster
Biological: Placebo booster

First Posted Date: 2020-12-16

Last Posted Date: 2022-07-08

Lead Sponsor: Arcturus Therapeutics, Inc.

Target Recruit Count: 581

Registration Number: NCT04668339

Locations: 🇸🇬
Arcturus Investigational Site 201, Singapore, Singapore
🇺🇸
Arcturus Investigational Site 107, Tucson, Arizona, United States
🇺🇸
Arcturus Investigational Site 112, San Diego, California, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy